Van Nieuwenhuysen, E., O’Malley, D., O’Cearbhaill, R. E., Moore, K. N., Hamilton, E. P., Yeku, O., Bouberhan, S., Hou, J. Y., Yoo, S.-Y., Brouwer-Visser, J., Cheung, H. K., Peterman, M., Goncalves, P., Schmidt, T., Zhu, M., Lowy, I., Rowlands, T., Uldrick, T. S., Miller, E. A., & Liu, J. F. (2022). 523MO Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis. Annals of Oncology, 33, S784. https://doi.org/10.1016/j.annonc.2022.07.651
Subjects:
Therapeutic Antibodies: Development, Engineering, and Applications
(OpenAlex Topic)
Role of Galectins in Immunity and Disease
(OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy
(OpenAlex Topic)
Publication Type:
Article
Unique ID:
10.1016/j.annonc.2022.07.651
Journal:
Publication Date:
Data Source:
OpenAlex
Source Link: